News for Akari Therapeutics, Plc (AKTX)

Akari Therapeutics (AKTX) to participate in the LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar. The event is scheduled for May

Live webcast on Thursday, May 29th at 2:20 PM ET BOSTON and LONDON, May 22, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc ( AKTX), an oncology biotechnol

NORWOOD, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. ( CRBP), a clinical-stage company focused on oncology and obesity, today

Advancing development of novel Antibody Drug Conjugates (ADCs) with immuno-oncology payloads to treat multiple cancer tumors Rounding out executive team with d

Akari Therapeutics (AKTX) is intensifying its focus on becoming a significant player in the antibody-drug conjugate (ADC) arena. The company's innovative ADC pl

Akari Therapeutics (AKTX) reports a reduced net loss of $3.7 million for Q1 2025, down from $5.6 million in Q1 2024. The company is focusing on developi

Akari Therapeutics (AKTX) appoints Mark F. Kubik as Head of Business Development - Oncology. Kubik brings over 25 years of experience in transformative

Global expertise in establishing and executing transformative transactions which have led to multiple approved therapeutic products Successful track record acr

On April 16, 2025, Akari Therapeutics PLC (AKTX) released its 8-K filing detailing its financial results for the fiscal year ending December 31, 2024. Akari The

In 2024, Akari Therapeutics (AKTX) underwent a significant transformation, marked notably by the successful merger with Peak Bio Inc. This strategic move has en

Advancing development of next-generation precision Antibody Drug Conjugates (ADCs) to address multiple indications across a range of cancer types Continued pr

Former SVP and Franchise Head for US Oncology at Jazz Pharmaceuticals, with established track record for leading a portfolio of products spanning both solid and

Former SVP and Franchise Head for US Oncology at Jazz Pharmaceuticals, with established track record for leading a portfolio of products spanning ...

**media[555729]**

**media[544651]**

Innovative targeted oncology company built on next-generation ADCs and a novel discovery engine Connect with the Company on Webull here BOSTON and LONDON,

Akari Therapeutics appoints Torsten Hombeck as Chief Financial Officer, effective December 16.

U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.28%

**media[460282]**